835 related articles for article (PubMed ID: 23696246)
21. Small molecule inhibition of fibroblast growth factor receptors in cancer.
Liang G; Chen G; Wei X; Zhao Y; Li X
Cytokine Growth Factor Rev; 2013 Oct; 24(5):467-75. PubMed ID: 23830577
[TBL] [Abstract][Full Text] [Related]
22. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
Dianat-Moghadam H; Teimoori-Toolabi L
Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
[TBL] [Abstract][Full Text] [Related]
23. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.
André F; Cortés J
Breast Cancer Res Treat; 2015 Feb; 150(1):1-8. PubMed ID: 25677745
[TBL] [Abstract][Full Text] [Related]
24. Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?
Bedussi F; Bottini A; Memo M; Fox SB; Sigala S; Generali D
Expert Opin Ther Targets; 2014 Jun; 18(6):665-78. PubMed ID: 24833241
[TBL] [Abstract][Full Text] [Related]
25. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
26. Fibroblast Growth Factor Receptor Signaling in Skin Cancers.
Czyz M
Cells; 2019 Jun; 8(6):. PubMed ID: 31167513
[TBL] [Abstract][Full Text] [Related]
27. Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.
Agrawal S; Maity S; AlRaawi Z; Al-Ameer M; Kumar TKS
Curr Drug Targets; 2021; 22(2):214-240. PubMed ID: 33045958
[TBL] [Abstract][Full Text] [Related]
28. The role of fibroblast growth factors and their receptors in prostate cancer.
Kwabi-Addo B; Ozen M; Ittmann M
Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
[TBL] [Abstract][Full Text] [Related]
29. De-regulated FGF receptors as therapeutic targets in cancer.
Knights V; Cook SJ
Pharmacol Ther; 2010 Jan; 125(1):105-17. PubMed ID: 19874848
[TBL] [Abstract][Full Text] [Related]
30. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
[No Abstract] [Full Text] [Related]
31. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
Katoh Y; Katoh M
Int J Mol Med; 2009 Mar; 23(3):307-11. PubMed ID: 19212647
[TBL] [Abstract][Full Text] [Related]
32. Expression and potential role of fibroblast growth factor 2 and its receptors in human embryonic stem cells.
Dvorak P; Dvorakova D; Koskova S; Vodinska M; Najvirtova M; Krekac D; Hampl A
Stem Cells; 2005 Sep; 23(8):1200-11. PubMed ID: 15955829
[TBL] [Abstract][Full Text] [Related]
33. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
[TBL] [Abstract][Full Text] [Related]
34. Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy.
Heinzle C; Sutterlüty H; Grusch M; Grasl-Kraupp B; Berger W; Marian B
Expert Opin Ther Targets; 2011 Jul; 15(7):829-46. PubMed ID: 21375471
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract][Full Text] [Related]
36. Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.
Lim SM; Kim HR; Shim HS; Soo RA; Cho BC
Future Oncol; 2013 Mar; 9(3):377-86. PubMed ID: 23469973
[TBL] [Abstract][Full Text] [Related]
37. Targeting FGFR Signaling in Cancer.
Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
[TBL] [Abstract][Full Text] [Related]
38. Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression.
Mori M; Mori T; Yamamoto A; Takagi S; Ueda M
Hum Cell; 2019 Jul; 32(3):367-378. PubMed ID: 30963412
[TBL] [Abstract][Full Text] [Related]
39. Future applications of FGF/FGFR inhibitors in cancer.
Ghedini GC; Ronca R; Presta M; Giacomini A
Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
[TBL] [Abstract][Full Text] [Related]
40. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]